Site hosted by Build your free website today!


June 7 /PRNewswire/ -- Incara Pharmaceuticals Corporation (Nasdaq: INCR - news) today announces the addition to its management team of two scientists with extensive drug development experience. Robert L. Susick, Ph.D joins the company as Vice President, Cell Technologies and will direct the liver precursor cell transplant program for treatment of liver failure. Richard E. Gammans, Ph.D. joins as Senior Vice President, Antioxidant Therapies and will direct the catalytic antioxidant program for treatment of stroke.

RESEARCH TRIANGLE PARK, N.C., March 31 /PRNewswire/ -- Incara Pharmaceuticals Corporation (Nasdaq: INCR) announced that it has acquired the remaining interests of its previously majority owned subsidiaries, Renaissance Cell Technologies, Inc. and Aeolus Pharmaceuticals, Inc., in exchange for Incara common stock. Incara previously owned approximately 78% of Renaissance and approximately 66% of Aeolus. Incara issued approximately 1.2 million new shares of its common stock for the subsidiaries' minority ownership. Following the transaction Incara has approximately 7.1 million shares of common stock outstanding.

"Because of promising developments in these subsidiaries, their programs have become a major focus for Incara," stated Clayton I. Duncan, President and CEO of Incara. "We believe that having Renaissance and Aeolus as wholly owned subsidiaries will allow Incara to more effectively operate as a single organization."

RESEARCH TRIANGLE PARK, N.C., Jan. 28 /PRNewswire/ -- Incara Pharmaceuticals Corporation (Nasdaq: INCR) today announced it has been notified by Nasdaq that Incara has been found to be in compliance with all requirements for continued listing on the Nasdaq National Market. As a result, Incara's previously announced hearing to determine listing compliance was considered moot and the hearing file will be closed. Incara will continue to be listed on the Nasdaq National Market.

Incara Pharmaceuticals Corporation conducts preclinical and clinical development with a diversified portfolio of compounds and therapies oriented to major advances in treatment of diseases afflicting large patient populations. The company currently is developing compounds and therapies for the treatment of inflammatory bowel disease, stroke, chronic bronchitis and cirrhosis of the liver.

Market Capitalization $18.1M

Shares Outstanding 5.11M

Float 2.00M